UK MHRA issues guidance on vigilance requirements of intraocular lenses
This article was originally published in SRA
The UK Medicines and Healthcare products Regulatory Agency has issued draft recommendations for manufacturers of CE-marked intraocular lenses and coronary stents on the notification of adverse events related to their products under the European medical device vigilance system1,2.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.